NGF Treatment for Patients With Neuropathic Corneal Pain
Status:
Withdrawn
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This prospective, single center, interventional, open-label, single arm, non-randomized trial
seeks to investigate the efficacy of Oxervate® (cenergermin 0.002% eye drops) on ameliorating
the signs and symptoms of neuropathic corneal pain (NCP). The study aims to enroll 28
subjects with NCP. All patients will be evaluated for clinical symptoms and signs of NCP,
corneal staining and nerve regeneration (by IVCM) at Baseline (Visit 2) through the end of
study (16 weeks post treatment).